Waldencast plc, through its subsidiary Obagi Medical, has announced a collaboration with VIO Med Spa as part of the new Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. VIO Med Spa was chosen as a key partner for its rapid growth and commitment to clinical excellence in advanced aesthetic treatments. The partnership will see VIO Med Spa conduct a multi-site, real-world assessment of Obagi® saypha® MagIQ™ across its national network, leveraging the spa’s expertise in injectables and patient-focused care. The initiative aims to generate robust clinical and patient experience data to enhance outcomes and advance the aesthetics industry.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Waldencast plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9645864-en) on January 30, 2026, and is solely responsible for the information contained therein.